全文获取类型
收费全文 | 2349篇 |
免费 | 108篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 95篇 |
妇产科学 | 20篇 |
基础医学 | 468篇 |
口腔科学 | 79篇 |
临床医学 | 259篇 |
内科学 | 516篇 |
皮肤病学 | 116篇 |
神经病学 | 67篇 |
特种医学 | 278篇 |
外科学 | 180篇 |
综合类 | 50篇 |
预防医学 | 121篇 |
眼科学 | 25篇 |
药学 | 152篇 |
中国医学 | 1篇 |
肿瘤学 | 54篇 |
出版年
2018年 | 26篇 |
2015年 | 30篇 |
2013年 | 83篇 |
2012年 | 32篇 |
2011年 | 28篇 |
2010年 | 50篇 |
2009年 | 35篇 |
2008年 | 26篇 |
2007年 | 56篇 |
2006年 | 48篇 |
2005年 | 30篇 |
2004年 | 28篇 |
2003年 | 28篇 |
2001年 | 32篇 |
2000年 | 30篇 |
1999年 | 35篇 |
1998年 | 84篇 |
1997年 | 95篇 |
1996年 | 105篇 |
1995年 | 71篇 |
1994年 | 74篇 |
1993年 | 77篇 |
1992年 | 48篇 |
1991年 | 39篇 |
1990年 | 43篇 |
1989年 | 68篇 |
1988年 | 60篇 |
1987年 | 52篇 |
1986年 | 54篇 |
1985年 | 42篇 |
1984年 | 56篇 |
1983年 | 28篇 |
1982年 | 32篇 |
1981年 | 39篇 |
1980年 | 50篇 |
1979年 | 25篇 |
1978年 | 29篇 |
1977年 | 37篇 |
1976年 | 40篇 |
1975年 | 40篇 |
1972年 | 25篇 |
1971年 | 25篇 |
1970年 | 23篇 |
1969年 | 22篇 |
1965年 | 50篇 |
1964年 | 50篇 |
1963年 | 47篇 |
1962年 | 41篇 |
1961年 | 40篇 |
1960年 | 65篇 |
排序方式: 共有2487条查询结果,搜索用时 31 毫秒
101.
Stem Cell Migration and Proliferation During Severe Anemia 总被引:3,自引:2,他引:3
RENCRICCA NICHOLAS J.; RIZZOLI VITTORIO; HOWARD DONALD; DUFFY PETER; STOHLMAN FREDERICK JR. 《Blood》1970,36(6):764-771
The pluripotential stem cell (CFU) compartment of marrow and spleen wasevaluated in mice subjected to an intense erythroid stimulus associated withphenylhydrazine-induced anemia. Erythroid hyperplasia occurred in both marrow and spleen. CFU in the marrowgradually declined to approximately 50per cent of control levels (day 5) whiletheir numbers in the spleen increased(fourfold) by day 3 and were maintainedat this level for several days. Thesechanges in numbers of marrow andsplenic CFU were not associated withCFU proliferation. Thereafter, CFU inthe marrow, but not in the spleen, entered active cell cycle. The data suggestthat CFU migrate from marrow to spleenduring the demands of severe anemia.The induction of marrow CFU into cyclefurther suggests a negative feedback,which, perhaps through cell-cell interaction, maintains stem cells at a criticalcompartment size. The failure of splenicCFU to cycle may reflect the converseeffect, i.e. an inhibition on stem cell proliferation in the wake of an expandedstem cell pool. Submitted on March 17, 1970 Revised on May 14, 1970 Accepted on June 9, 1970 相似文献
102.
Shelf-price agreements: the next frontier in competitive bidding for coronary intervention supplies.
Robert K Keast Kim A Eagle Julie Goldstein-Dunn Douglas Cox Catherine Gage Michalak Stanley Chetcuti P Michael Grossman Debabrata Mukherjee Linda R Larin Stephen Fetyko T Anthony Denton Mauro Moscucci 《The Journal of cardiovascular management》2005,16(3):27-30
In an attempt to further reduce operating costs, in 2004 our institution embarked on a novel approach in which we defined the price to be paid for interventional cardiology supplies and challenged vendors to meet that price. The results suggest that this strategy can further reduce supply costs while maintaining collaborative relationships with vendors. 相似文献
103.
Hasegawa DK; Bennett AJ; Coccia PF; Ramsay NK; Nesbit ME; Krivit W; Edson JR 《Blood》1980,56(4):585-595
Factor V deficiency has been identified in 8 of 8 patients 7--20 yr of age, with Philadelphia-positive (Ph1+) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10%--12% (0.10--0.12 U/ml) after the infusion of 28--31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18% of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph1+ CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20--80 yr, with Ph1+ CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid- megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders. 相似文献
104.
Alexsandra R.m. Favacho Isabelle Roger Amanda K. Akemi Adonai A. Pessoa JR. Andrea G. Varon Raphael Gomes Daniela T. Godoy Sandro Pereira Elba R.s. Lemos 《Revista do Instituto de Medicina Tropical de S?o Paulo》2014,56(4):363-365
Bartonella henselae is associated with a wide spectrum of clinical
manifestations, including cat scratch disease, endocarditis and meningoencephalitis,
in immunocompetent and immunocompromised patients. We report the first molecularly
confirmed case of B. henselae infection in an AIDS patient in state
of Rio de Janeiro, Brazil. Although DNA sequence of B. henselae has
been detected by polymerase chain reaction in a lymph node biopsy, acute and
convalescent sera were nonreactive. 相似文献
105.
106.
107.
EDWARD J. SWIFT JR. DMD MS 《Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]》2012,24(4):287-291
This is the second part of a two‐part piece on self‐adhesive resin cements; Part I was presented in the previous issue of the Journal. Here in Part II, the specific topics concerning self‐adhesive cements are clinical performance, post‐cementation sensitivity, and cementation of endodontic posts. 相似文献
108.
R Idro K A Musubire B Byamah Mutamba H Namusoke J Muron C Abbo R Oriyabuzu J Ssekyewa C Okot D Mwaka P Ssebadduka I Makumbi B Opar JR Aceng AK Mbonye 《African health sciences》2013,13(2):219-232
Nodding Syndrome is a poorly understood neurologic disorder of unknown aetiology that affects children and adolescents in Africa. Recent studies have suggested that the head nods are due to atonic seizures and Nodding Syndrome may be classified as probably symptomatic generalised epilepsy. As part of the Ugandan Ministry of Health clinical management response, a multidisciplinary team developed a manual to guide the training of health workers with knowledge and skills to manage the patients. In the absence of a known cause, it was decided to offer symptomatic care. The objective is to relieve symptoms, offer primary and secondary prevention for disability and rehabilitation to improve function. Initial management focuses on the most urgent needs of the patient and the immediate family until ‘stability’ is achieved. The most important needs were considered as seizure control, management of behavioural and psychiatric difficulties, nursing care, nutritional and subsequently, physical and cognitive rehabilitation. This paper summarises the processes by which the proposed guidelines were developed and provides an outline of the specific treatments currently being provided for the patients. 相似文献
109.
Robert S. Kirsner MD PhD Wolfgang Vanscheidt MD David H. Keast MD John C. Lantis MD II Cyaandi R. Dove DPM Shawn M. Cazzell DPM Mher Vartivarian DPM Matthias Augustin MD William A. Marston MD Nicholas D. McCoy BS D. Innes Cargill PhD Tommy D. Lee MSHS Jaime E. Dickerson PhD Jr Herbert B. Slade MD for the HP‐ Study Group 《Wound repair and regeneration》2016,24(5):894-903
In 2012 we reported promising results from a phase 2 clinical trial of HP802‐247, a novel spray‐applied investigational treatment for chronic venous leg ulcers consisting of human, allogeneic fibroblasts and keratinocytes. We now describe phase 3 clinical testing of HP802‐247, its failure to detect efficacy, and subsequent investigation into the root causes of the failure. Two randomized, controlled trials enrolled a total of 673 adult outpatients at 96 centers in North America and Europe. The primary endpoint was the proportion of ulcers with confirmed closure at the end of 12 weeks of treatment. An investigation into the root cause for the failure of HP802‐247 to show efficacy in these two phase 3 trials was initiated immediately following the initial review of the North American trial results. Four hundred twenty‐one patients were enrolled in the North American (HP802‐247, 211; Vehicle 210) and 252 in the European (HP802‐247, 131; Vehicle 121) trials. No difference in proportion of closed ulcers at week 12 was observed between treatment groups for either the North American (HP802‐247, 61.1%; Vehicle 60.0%; p = 0.5896) or the European (HP802‐247, 47.0%; Vehicle 50.0%; p = 0.5348) trials. Thorough investigation found no likelihood that design or execution of the trials contributed to the failure. Variability over time during the trials in the clinical response implicated the quality of the cells comprising HP802‐247. Concordance between the two separate, randomized, controlled trials with distinct, nonoverlapping investigative sites and independent monitoring teams renders the possibility of a Type II error vanishingly small and provides strong credibility for the unexpected lack of efficacy observed. The most likely causative factors for the efficacy failure in phase 3 was phenotypic change in the cells (primarily keratinocytes) leading to batch to batch variability due to the age of the cell banks. 相似文献
110.